NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Introduces Practical Solutions for Translational Science - The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering - RandoxPharmaServices.com
Randox Introduces Practical Solutions for Translational Science

 

NewswireTODAY - /newswire/ - Crumlin, Antrim, United Kingdom, 2011/05/23 - The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering - RandoxPharmaServices.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Randox Pharma Services was founded with such a translational mission, and for 30 years has been carrying out R&D, custom assay development and supplying diagnostic solutions; all underpinned by a strong commitment to collaborate with leading academic research centres and pharmaceutical companies globally.

In recognition of the vital role biomarkers play in translational medicine, Randox Pharma Services supply an unrivalled range of single analyte and multiplex diagnostic kits direct to end user laboratories. Indeed, even kits produced primarily for research come under the same scrutiny as any commercial IVD assay i.e. imprecision less than 10%, fully optimised to eliminate cross-reactivity and non-specific binding to name just a few of our stringent QA processes.

As a private company Randox Pharma Services can be flexible and are swift to focus our significant in-house resources and expertise towards any pressing healthcare need; with a particular focus on oncology, infectious disease and metabolic disorders.

To enable this Randox have developed Biochip Array Technology, a multiplex technology which allows the simultaneous detection of multiple biomarkers from a single patient sample. Given the increased value of multiple biomarkers to improve patient diagnosis, such a technology is the ideal ‘target platform’ for translational science. Already arrays have been developed which are applicable to a broad range of therapeutic areas, with applications including multiplex immunoassays and nucleic acid based SNP, mutation, gene expression and pathogen detection arrays.

Randox Pharma Services (randoxpharmaservices.com) also offer over 130 enzymatic, substrate and immunoturbidimetric assays on our class-leading range of RX Series chemistry analysers which provide quality results at every phase from pre-clinical testing through to the clinic.

With robust, fit-for-purpose assays a pre-requisite for research, biomarker validation and ultimately translational science, only an established clinical diagnostic company such as Randox has the scientific and regulatory experience required. All to meet the pressing need for the more rapid translation of novel biomarkers to clinical utility.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Randox Introduces Practical Solutions for Translational Science

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832 pharmaservices[.]randox.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)